Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment

Table 3

The information of the first 20 KEGG pathways enriched by upregulated CXCR2-relevant genes.

Description	GeneRatio	BgRatio	value	FDR	Size
Staphylococcus aureus infection	39/411	96/8009	7.16-26	1.90-23	39
Hematopoietic cell lineage	38/411	99/8009	3.70-24	4.90-22	38
Phagosome	44/411	152/8009	4.61-22	3.62-20	44
Rheumatoid arthritis	35/411	93/8009	5.46-22	3.62-20	35
Leishmaniasis	31/411	77/8009	1.26-20	6.68-19	31
Tuberculosis	45/411	180/8009	1.02-19	4.52-18	45
Viral protein interaction with cytokine and cytokine receptor	32/411	100/8009	9.47-18	3.58-16	32
Cytokine-cytokine receptor interaction	54/411	294/8009	5.80-17	1.92-15	54
Cell adhesion molecules (CAMs)	36/411	147/8009	1.17-15	3.46-14	36
Osteoclast differentiation	32/411	128/8009	2.59-14	6.87-13	32
Inflammatory bowel disease (IBD)	23/411	65/8009	3.66-14	8.81-13	23
Allograft rejection	18/411	38/8009	5.50-14	1.22-12	18
Chemokine signaling pathway	38/411	189/8009	1.71-13	3.49-12	38
Human T cell leukemia virus 1 infection	41/411	219/8009	2.24-13	4.24-12	41
Graft-versus-host disease	18/411	41/8009	2.87-13	5.07-12	18
Type I diabetes mellitus	18/411	43/8009	7.86-13	1.30-11	18
Th17 cell differentiation	27/411	107/8009	2.29-12	3.57-11	27
Antigen processing and presentation	23/411	78/8009	2.99-12	4.40-11	23
Influenza A	34/411	170/8009	4.03-12	5.63-11	34
Asthma	15/411	31/8009	4.95-12	6.57-11	15